comparemela.com

Latest Breaking News On - Sleep wake disorders center - Page 1 : comparemela.com

Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024

Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced five presentations, including two featured oral plenary presentations, on.

United statesNew yorkNordrhein westfalenHans van dongenMark jacobsonDarren oplandMichael thorpySamantha floamJohannes gutenbergDepartment of neurologyMontefiore medical centerProfessor at washington state universityAmerican academy of sleep medicineAxsome therapeutics incCorporate communicationsDrug administration

Axsome to Present Findings on Solriamfetol s Cognitive Benefits

Axsome will unveil data demonstrating solriamfetol's ability to enhance cognitive functioning in patients with OSA and narcolepsy.

Nordrhein westfalenJohannes gutenbergMichael thorpySolriamfetol sunosiUlf kallweitHans van dongenSamantha floamWashington state universityMontefiore medical centerWake disorders centerDepartment of neurologyAxsome therapeutics incMedicine centerUniversity witten herdeckeAxsome therapeuticsTherapeutics inc

Avadel to Present Data on Lumryz for Narcolepsy at SLEEP 2024

At SLEEP 2024, Avadel will present new data on Lumryz, the first extended-release, once-nightly formulation of sodium oxybate for narcolepsy.

United statesMichaelj thorpyMaggie lavenderJennifer gudemanDrug administrationWake disorders center at montefioreAvadel pharmaceuticalsGeorger brown convention centerMedicine associatesRisk evaluationMitigation strategyComprehensive sleep medicine associatesSleep wake disorders centerAlbert einstein college

Psychiatry in the News: March 2024

Here are some updates from the world of psychiatry throughout the month of March.

Johnj millerMichael thorpyPimavanserin nuplazidDrug administrationAlbert einstein college of medicineWake disorders centerAcadia pharmaceuticalsMontefiore medical centerPsychiatric timesNarcolepsy meets primaryOrphan drug designationSleep wake disorders centerAlbert einstein collegeCandidate pimavanserin failsAchieve primary efficacyStar advanced therapy

Phase 3 Trial of AXS-12 for Narcolepsy Meets Primary Endpoint

The treatment significantly reduced the frequency of cataplexy attacks in patients with narcolepsy compared with placebo.

Herriot tabuteauMichael thorpyWake disorders centerAlbert einstein college of medicineMontefiore medical centerOrphan drug designationSleep wake disorders centerAlbert einstein collegeAxsome therapeuticsAccessed march

vimarsana © 2020. All Rights Reserved.